Latest news for WedoTalk (OTC:WDTK) Stock

WedoTalk Inc, formerly Shentang International Inc is a Shell company.

WedoTalk Inc

Bell to expand use of the ServiceNow platform to augment tech services portfolio for Bell Business Markets enterprise customers as well as transform its network and IT infrastructure
Now Platform to streamline business-critical areas for Bell, including Network, Customer, Field Service Operations, and Corporate Services
MONTRÉAL&nbsp;and&nbsp;SANTA&nbsp;CLARA, Calif., July 18, 2024 /CNW/ -&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4214431-1&amp;h=517228798&amp;u=https%3A%2F%2Fwww.bell.ca%2F&amp;a=Bell+Canada">Bell Canada</a>, Canada's communications, tech services and digital media leader, and&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4214431-1&amp;h=3119280436&amp;u=http%3A%2F%2Fwww.servicenow.com%2F&amp;a=ServiceNow">ServiceNow</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), the AI platform for business transformation, today announced&nbsp;a multi-year strategic agreement to accelerate Bell's transformation to meet the growing customer demand for tech services and digital media. The renewed commitment makes Bell one of ServiceNow's largest communications customers with a first of its kind collaboration in Canada.&nbsp;Bell will expand its use of the ServiceNow platform, supporting its own digital transformation while continuing to offer ServiceNow implementation expertise to support the digital transformation of its Bell Business Markets customers.

News

Bell Canada And ServiceNow Announce Expanded Multi-Year Strategic Agreement, Supporting Its Own Digital Transformation While Continuing To Offer ServiceNow Implementation Expertise To Support The Digital Transformation Of Its Bell Business Markets Customers

Evolv Becomes A Part of Guest Experience Improvements at Windy City Landmark
Evolv Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>), a leading security technology company pioneering AI-based screening to create safer experiences, today announced its partnership with 360 CHICAGO, the observation deck and immersive experience on the 94th floor of 875 N Michigan Avenue, formerly the John Hancock Center in Chicago, Illinois.
360 CHICAGO uses an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evolvtechnology.com%2Fproducts%2Fevolv-express&amp;esheet=54095938&amp;newsitemid=20240718546656&amp;lan=en-US&amp;anchor=Evolv+Express&amp;index=1&amp;md5=25335a8bd966037216ae9d4723b8ee0d">Evolv Express</a>&#xAE; system to screen guests before they take the elevator up to the experience, which includes the TILT thrill ride and CloudBar, a cocktail lounge with panoramic views of the city. The system was installed in August 2023 after venue officials saw Evolv screening fans attending a local sporting event. 360 CHICAGO used to conduct manual bag checks at entry. When it recently underwent renovations, it included Evolv in a number of upgrades.

EVLV

Evolv Technology Elevates 360 CHICAGO Experience, Evolv Becomes A Part Of Guest Experience Improvements At Windy City Landmark

Truist Securities analyst Barry Jonas maintains Light &amp; Wonder (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) with a Buy and raises the price target from $115 to $120.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Light & Wonder, Raises Price Target to $120

Macro Economic Events

Macro Notification

Economics

General

ECB Leaves Rates Unchanged

Pure Biologics' exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.twistbioscience.com%2F&amp;esheet=54096019&amp;newsitemid=20240718647518&amp;lan=en-US&amp;anchor=Twist+Bioscience+Corporation&amp;index=1&amp;md5=a8252773dd773dfe5623b7bd1012baf5">Twist Bioscience Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the first patient has been dosed in Pure Biologics' exploratory Phase 0 clinical study of PBA-0405. PBA-0405 is a fully human IgG1 antibody that was discovered using Twist Biopharma Solutions' synthetic antibody phage display libraries. Twist Biopharma Solutions, a division of Twist Bioscience, provides an integrated offering of in vitro, in vivo, and in silico tools for antibody discovery research. This exploratory study is designed to provide early insights into the biological effects of PBA-0405 within the tumor environment.

Biotech

TWST

Twist Bioscience Announces Clinical Progression Of Pure Biologics' Antibody Candidate Discovered Using Twist's Antibody Libraries

TD Cowen analyst Gregory Williams maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Buy and raises the price target from $124 to $127.

TD Cowen Maintains Buy on Crown Castle, Raises Price Target to $127

Truist Securities analyst Barry Jonas maintains Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) with a Buy and lowers the price target from $43 to $40.

GDEN

Truist Securities Maintains Buy on Golden Entertainment, Lowers Price Target to $40

Contracts

Global

Dr. Reddy's Signs Non-Exclusive Patent Licensing Agreement With Takeda To Commercialize Vonoprazan In India

NKGen will present data on SNK01&#39;s ability to reduce &alpha;-synuclein in Alzheimer&#39;s patients, which is significant given that &alpha;-synuclein has been shown to correlate with worse cognitive function in Alzheimer&#39;s disease.

Health Care

NKGN

NKGen Biotech Will Present New Biomarker Data On SNK01 (Autologous Non-genetically Modified Nk Cell Therapy) In Alzheimer's Disease During A Poster Presentation At The Upcoming Alzheimer's Association International Conference From July 28 – August 1

Facebook owner considers multibillion investment in European eyewear group to expand smart glasses partnership
 <a href="https://www.ft.com/content/4da37b6a-b241-4090-9445-467087694ab7" title="https://www.ft.com/content/4da37b6a-b241-4090-9445-467087694ab7">https://www.ft.com/content/4da37b6a-b241-4090-9445-467087694ab7</a>

'Meta explores stake in Ray-Ban maker EssilorLuxottica' - Financial Times

Calidi Biotherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. &nbsp;
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,036,278 titled, "Smallpox Vaccine for Cancer Treatment," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.

CLDI

Calidi Biotherapeutics Receives Issuance Of New U.S. Patent Covering Novel SuperNova Technology Platform

Southern California Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAL#NASDAQ">BCAL</a>), the holding company for Bank of Southern California, N.A., and California BanCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALB#NASDAQ">CALB</a>), the holding company for California Bank of Commerce, announce that at meetings of their respective shareholders held on July 17, 2024, Southern California Bancorp and California BanCorp shareholders approved the merger of California BanCorp with and into Southern California Bancorp, with Southern California Bancorp the surviving corporation pursuant to the Merger Agreement, dated January 30, 2024, by and between Southern California Bancorp and California BanCorp. &nbsp;
Shareholders of Southern California Bancorp also approved a change of the company's name from Southern California Bancorp to California BanCorp and an amendment to Southern California Bancorp's bylaws to change the allowable range of members of the board of directors to seven to 13, from its previous range of six to 11.

BCAL

CALB

Southern California Bancorp And California BanCorp Announce Receipt Of Shareholder Approvals For Merger

JP Morgan analyst Joseph Greff downgrades Melco Resorts and Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLCO#NASDAQ">MLCO</a>) from Overweight to Neutral and lowers the price target from $10 to $7.

Downgrades

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

JP Morgan Downgrades Melco Resorts and Enter to Neutral, Lowers Price Target to $7

Small Cap Consumer Research analyst Eric Beder maintains Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) with a Buy and raises the price target from $17 to $20.

Small Cap Consumer Research Maintains Buy on Lands' End, Raises Price Target to $20

Infosys Ltd&nbsp;(NYSE:&nbsp;INFY) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n39834317/infosys-stellar-all-round-performance-with-3-6-sequential-revenue-growth-in-cc-1-operating-margin-" rel="noreferrer noopener">first-quarter revenue</a> growth of 2.5% in constant currency terms year-on-year to $4.71 billion, beating the analyst consensus estimate of $4.65 billion. The stock price gained after the print.
Revenues in constant currency terms increased by 3.6%&nbsp;quarter over quarter. EPS of $0.18 is in line with the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Street analyst estimate</a> and up from $0.17 a year ago.
Infosys&nbsp;said the number of large deal wins was highest ever at 34, with TCV of&nbsp;$4.1 billion,&nbsp;57.6%&nbsp;being net new. The operating margin improved by 30 bps to 21.1%.&nbsp;
Infosys held $1.97 billion in cash and equivalents as of June-end. It generated a free cash flow of $1.09 billion, which grew 56.5% year-over-year at a conversion of 143.2% of net profit.
Jayesh Sanghrajka, CFO, said, &#8220;We had the highest ever FCF generation at&nbsp;$1.1 bn&nbsp;and ROE increased to 33.6% due to higher payouts to investors.&#8221;
FY25 Revenue Outlook: Infosys expects revenue growth of 3.0%-4.0% (<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38314474/infosys-stock-falls-after-q4-earnings-whats-going-on" rel="noreferrer noopener">prior 1.0% – 3.0%</a>) in constant currency vs.&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus $19.04 billion</a>. The company reiterated its operating margin outlook of 20% &#8211; 22%.
Price Action: INFY shares traded higher by 4.92% at $21.54 in the premarket on the last check Thursday.
Image: Shutterstock/ IgorGolovniov

Earnings

Equities

Guidance

Movers

INFY

Infosys Reports Strong Q1 Earnings, Records Highest Free Cash Flow Ever

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) suffered under the wake of a broader technology sector rout, with presidential candidate Donald Trump suggesting that<a href="https://www.benzinga.com/news/24/07/39807774/trump-says-taiwan-should-pay-us-for-defense-ex-presidents-remark-triggers-fall-in-tsmc-shares"> Taiwan should compensate the U.S. for its defense</a>. As for the tech powerhouse, while Wall Street analysts are overwhelmingly bullish on META stock, concerns about forward viability have started to impact the current price action.
On the positive front, the social media giant – which owns Facebook along with other popular digital properties – recently<a href="https://www.benzinga.com/news/24/07/39803195/meta-platforms-stock-is-trading-lower-tuesday-whats-going-on"> received a major endorsement</a>. On Tuesday, Wolfe Research initiated coverage of META stock, pegging it with an<a href="https://www.benzinga.com/analyst-stock-ratings"> Outperform rating</a> along with a price target of $620. Against the close of the July 17 session, the forecast represents a return of 34.2%.
Wolfe's Shweta Khajuria stated in a research note to clients that Meta benefits from its massive scale, along with robust growth in its top line. In addition, the expert stated that META stock could enjoy a tailwind from the underlying company's investments in artificial intelligence.
Most importantly, Khajuria believes that Meta's advertising platform represents a must-have solution for digital-centric enterprises. However, it's the ad ecosystem itself that has also contributed to challenges for META stock.
An<a href="https://www.statista.com/statistics/267031/facebooks-annual-revenue-by-segment/#:~:text=Meta%3A%20annual%20revenue%202009%2D2023%2C%20by%20segment&amp;text=In%202023%2C%20Meta%20Platforms%20generated,Instagram%2C%20Messenger%2C%20and%20WhatsApp."> overwhelming percentage</a> of the tech juggernaut's revenue stems from its digital ad business. However, in prior months, significant issues related to this advertising system contributed to<a href="https://www.benzinga.com/news/24/04/38216195/elon-musk-asks-advertisers-to-return-to-x-after-months-of-tussle-with-disney-apple-and-others-as-zuc"> higher costs and poorer results</a> for marketing clients.
Further, skeptics will note that in terms of<a href="https://www.benzinga.com/quote/META/earnings"> earnings surprises</a> – or the magnitude by which bottom-line results beat analysts' targets – the trend has been decisively negative since the third quarter of 2023. In other words, there's plenty of fodder for both bulls and bears of META stock.
The ETFs: Given the rich backdrop of narratives, this framework provides ample relevance for META-specific exchange-traded funds. First, the Direxion Daily META Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METU#NASDAQ">METU</a>) provides 2X exposure to the tech juggernaut. Because of the compounding effect, METU is only appropriate for positions opened and closed within the same day. At the same time, speculators could see their returns accelerate considerably if they happen to call the market correctly.
On the other end of the scale, the Direxion Daily META Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METD#NASDAQ">METD</a>) provides a 1X inverse exposure to META stock; that is, as the target equity falls in value, this ETF rises. However, because of the similar compounding effect, investors should be in and out of their position within the same day.
The METU Chart: Since its introduction in early June to the first few days of July, METU witnessed a significant surge in value. However, as selling pressure impacted META stock, the leveraged fund witnessed a considerable erosion in sentiment.
<ul>
<li>The July 17 session saw METU drop more than 11% as tech sector woes dragged down large-capitalization innovators.</li>
<li>In the technical charts, METU printed a red candlestick with no upper wick or shadow. This dynamic may indicate that sellers dominate the market.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-us.googleusercontent.com/docsz/AD_4nXdxYuZ_XQWfOGUd7hgFRiG2np3FgocY_OvN7bI_2yJiWPaTRxKx1IzuV6nS_ZhKU95UB_iDrB44x9k_CjqceS-nWzUIq4m03vg_r7V6MGvpqKoVL6W9zGDCHn1N8PDe0im-zbQ_hV1zpslqRTEuP3cUufs?key=Yv_zyK3o5tO8EHn4HVQgRQ" alt="" /></figure>
The METD Chart: As expected, the trend of the METD ETF represented the inverse of META stock, slipping during the period between early June and early July. However, in the past few sessions, the bear fund rocketed higher as top-tier tech names struggled under volatile pressure.
<ul>
<li>On July 17, METD gained 5.87% of market value, which was almost the exact inverse performance of META stock, which dropped 5.68%.</li>
<li>METU charted a white candlestick with no lower wick or shadow. This suggests that from the opening bell, pessimists were bullish on the inverse fund (meaning bearish on the underlying asset), thus establishing control of the market.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-us.googleusercontent.com/docsz/AD_4nXfCRHYih6FhVqCWHFqHS_Nv4h3dAO60XMiFY3BoC4UEYair1PHhOv-70aznv6OBG-siqoNO2WcWg0vkWW8uEb1Cuzsdj5pdGUaTIAJW_5JLQ7nc4qgfDa9QQpjbwAMZPtcF8bMgCoroC6Ec8_uvYub4mf0?key=Yv_zyK3o5tO8EHn4HVQgRQ" alt="" /></figure>
Featured photo by <a href="https://pixabay.com/users/lobostudiohamburg-13838/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=292994">Thomas Ulrich</a> from <a href="https://pixabay.com//?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=292994">Pixabay</a>.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

METD

METU

Direxion's METU And METD Funds Allow Traders To Play Both Sides Of Meta Platforms Stock

Truist Securities analyst Barry Jonas maintains Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) with a Buy and raises the price target from $145 to $165.

CHDN

Truist Securities Maintains Buy on Churchill Downs, Raises Price Target to $165

PHAT

The FDA Approved Phathom Pharmaceuticals' Voquezna (Vonoprazan) 10 mg Tablets For Heartburn Associated With Non-erosive Gastroesophageal Reflux Disease In Adults, This Is The Third FDA Approval For Voquezna

<ul>
<li>New product tunes into trending topics to accelerate ad spend at peak conversation velocity, and pause when conversation slows</li>
<li>Record engagement across X from brands using the product</li>
</ul>
Ahead of a summer of sport, including the Olympic &amp; Paralympic Games, X and Genius Sports Limited ("Genius Sports") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) have announced the launch of the Trend Genius product, leveraging real-time conversations to accelerate ad attention in moments that matter.
The new technology, built by Genius Sports and powered by X's Ads and Trend APIs, allows advertisers to align with the real-time conversations happening on the X platform across categories. When a specified topic organically reaches a set conversation velocity, pre-programmed creative will run to reach audiences when they're most engaged.
When conversation naturally quiets, campaigns are automatically paused until the topic accelerates again. As the exclusive data distributor for the NFL, NCAA, and the Premier League, Genius Sports relied on its heritage of building data-driven products to engineer real-time algorithms needed to start and stop ad spend across the X platform.

GENI

X And Genius Sports Partner To Launch Trend Genius Product Ahead Of Major Summer Sporting Events

Small Cap Consumer Research analyst Eric Beder reiterates Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) with a Buy and maintains $22.5 price target.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

WedoTalk

News

Latest news for WedoTalk (OTC:WDTK) Stock